ARA-290, also called cibinetide or PHBSP, is an investigational erythropoietin-derived peptide studied in early human trials for neuropathy-related conditions. It is not a standard approved treatment, and many online products are labeled for research use only. Chia does not offer ARA-290; patients should discuss legal, safety, and evidence questions with a licensed clinician.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy ARA-290 peptide in the USA?
ARA-290 can be found on some commercial peptide websites, but that does not make it a patient-ready medication. Many listings describe it as a lyophilized powder for laboratory or research use, not for human use, and some list vial amounts such as 15 mg or 16 mg as product content rather than a prescribed dose 8, 9.
Why many online ARA-290 products are labeled “research use only”
A research-use label usually means the seller is positioning the product for laboratory work, not for human administration. One ARA-290 listing states it is “not a drug, food, cosmetic, or dietary supplement” and is not intended for human or veterinary use 8.
Why buying a peptide is different from receiving a prescribed medication
A prescribed medication involves a clinician review, a medical reason to use it, screening for risks, a plan for monitoring, and dispensing through a legitimate pharmacy. A vial sold online as a research chemical may not come with medical oversight, sterility standards for injection, patient-specific directions, or a way to manage side effects; FDA also advises patients to use safe online pharmacy practices and avoid illegitimate sellers 10.
What to ask before considering any peptide sold online
- Is a licensed clinician evaluating whether this is appropriate for me?
- Is the product dispensed by a state-licensed pharmacy, or is it sold as a research chemical?
- Is it intended for human use, or does the listing say “research use only”?
- Is there human evidence for my condition, not just animal or cell data?
- Are side effects, contraindications, and monitoring explained clearly?
Quick facts about ARA-290
ARA-290 is also called cibinetide or PHBSP. It is described in human research as a nonhematopoietic, erythropoietin-derived peptide; in one phase 2 trial, researchers studied 4 mg given subcutaneously daily for 28 days, with follow-up through 56 days 1, 2.
| Question | Short answer |
|---|---|
| Other names | Cibinetide, PHBSP, ARA 290 |
| Drug class | Investigational non-erythropoietic erythropoietin-derived peptide |
| Proposed mechanism | Innate repair receptor signaling involving EPOR and beta-common receptor CD131 pathways |
| Human research areas | Painful diabetic neuropathy and sarcoidosis-associated small fiber neuropathy |
| Chia availability | Chia does not currently offer ARA-290, cibinetide, PHBSP, or compounded ARA-290 |
What is ARA-290, and why are people searching for it?
ARA-290 is a synthetic peptide modeled from erythropoietin research. People search for it because early studies explored nerve symptoms and tissue-protective pathways, but those studies do not prove broad benefits for wellness, longevity, or self-directed use.
ARA-290, cibinetide, and PHBSP: names patients may see
ARA-290, cibinetide, and PHBSP refer to the same research peptide in common patient-facing discussions. In the diabetes neuropathy trial, authors described ARA-290 as a nonhematopoietic peptide designed from erythropoietin and studied over a 56-day observation period 1.
How ARA-290 differs from erythropoietin
Erythropoietin, often shortened to EPO, is known for its role in red blood cell production. ARA-290 was designed to study tissue-protective signaling without the erythropoietic, or red-blood-cell-stimulating, activity that can create safety concerns with EPO-like effects 1, 4.
Why neuropathy, inflammation, and tissue-repair claims need careful reading
The careful version is this: ARA-290 has been investigated for specific neuropathy-related conditions in early human trials. The stronger claim—that it treats nerve pain, repairs tissue, or supports longevity in a general way—is not established by the available human evidence 1, 3.
What does the human research on ARA-290 actually show?
ARA-290 has early human data, but not the kind of large, long-term evidence used to support routine treatment. The main studies patients find online are small or phase 2 studies, including a diabetic neuropathy study with 28 days of treatment 1, 2.
Phase 2 study in type 2 diabetes with painful neuropathy
In a phase 2 study of people with type 2 diabetes and painful neuropathy, ARA-290 4 mg or placebo was self-administered subcutaneously daily for 28 days, then participants were followed for another month without treatment 1. That dose is a study detail, not a patient instruction.
The study reported improvements in HbA1c, lipid profiles, PainDetect neuropathic symptom scores, and corneal nerve fiber density in a subgroup with reduced baseline nerve fiber density 1. The same study reported no potential safety issues during the study period, but the short trial length means it cannot establish long-term safety or predictable results for patients; individual results vary.
Pilot randomized study in sarcoidosis-associated small fiber neuropathy
ARA-290 was also studied in a randomized, double-blind pilot study in sarcoidosis patients with small fiber neuropathy symptoms 3. Sarcoidosis is an inflammatory disease, and small fiber neuropathy can cause burning pain, tingling, and autonomic symptoms; evidence from that setting should not be stretched to unrelated conditions.
What corneal nerve fiber density means—and what it does not prove
Corneal nerve fiber density is measured in the eye and can be used as a marker of small nerve fiber health. In the diabetes neuropathy study, a subgroup showed increased corneal nerve fiber density compared with placebo, but a biomarker change does not prove long-term pain relief, disease modification, or benefit for general health 1.
Why early trials do not establish routine treatment use
Early trials are useful because they help researchers decide whether a treatment deserves further study. They do not answer every patient question about long-term side effects, best candidates, drug interactions, pregnancy risk, dosing outside the study, or outcomes across broad groups.
How is ARA-290 thought to work?
ARA-290 is thought to act through tissue-protective receptor pathways rather than the classic red-blood-cell pathway of erythropoietin. The proposed target is often called the innate repair receptor, with signaling involving EPOR and the beta-common receptor CD131; this is a mechanism model, not proof of patient benefit 1, 5.
The proposed innate repair receptor pathway
The innate repair receptor is a proposed tissue-response pathway studied in injury, inflammation, and nerve models. ARA-290 was designed to interact selectively with that pathway, which researchers hoped could separate tissue-protective signals from erythropoietin’s blood-cell effects 1, 5.
EPOR, beta-common receptor CD131, and tissue-protective signaling
In simple terms, EPOR is the erythropoietin receptor, and CD131 is a shared beta receptor involved in several cytokine pathways. Preclinical work proposed that tissue-protective signaling may involve receptor complexes different from those driving red blood cell production 4, 5.
Why “non-erythropoietic” matters
“Non-erythropoietic” means a compound is designed not to stimulate red blood cell production in the way erythropoietin can. That matters because red-blood-cell effects can create safety concerns, but design intent does not remove the need for human safety data 1.
Preclinical mechanisms versus proven patient outcomes
Mechanism studies can explain why scientists are interested in a peptide. They cannot tell a patient whether a product bought online is safe, pure, sterile, legal, or likely to help their symptoms.
How long does ARA-290 take to work in studies?
ARA-290 trial timelines should not be used as personal treatment expectations. In the type 2 diabetes neuropathy study, researchers measured outcomes after 28 days of daily study treatment and followed participants through 56 days 1, 2.
What was measured after 28 days in the type 2 diabetes neuropathy study
Researchers looked at several outcomes, including neuropathic symptoms using the PainDetect questionnaire, metabolic markers such as HbA1c and lipid profiles, and corneal nerve fiber density 1. These are different kinds of outcomes, and they do not all mean the same thing.
Why trial timelines cannot be used as personal treatment expectations
A trial timeline is chosen for research reasons. It does not tell an individual patient when they would feel a change, whether they should use the compound, or whether their health history makes the risk too high.
Why symptom changes, biomarkers, and nerve-fiber measures are different outcomes
A symptom score reflects what a participant reports. A biomarker such as HbA1c or a lipid value reflects a lab measure. Corneal nerve fiber density reflects a nerve-related imaging marker. A useful trial can measure all three, but none alone proves broad benefit.
What are the risks of buying ARA-290 online?
ARA-290 sold online may be a research chemical rather than a medication made for a specific patient. That creates practical risks around identity, purity, sterility, storage, dosing confusion, injection technique, side effects, and legal status; one listing even states storage at −20°C for laboratory handling 8.
Research-use products are not the same as prescribed medicines
A research-use product may be intended for analytical or laboratory work only. If the product is not intended for human use, the seller’s certificate, purity claim, or vial size does not turn it into a prescription medication 8, 9.
Purity, sterility, storage, and identity concerns
Peptides can be sensitive to handling and storage. For injectable use, sterility matters as much as identity and purity. A product may list a purity percentage, but patients still need to know whether it was made, tested, stored, and dispensed under standards appropriate for human medication.
Why self-injection without clinician oversight can be unsafe
Self-injection can cause infection, dosing errors, allergic reactions, and delayed care if a serious condition is being self-managed. The early ARA-290 trials were conducted with research protocols and follow-up; that is very different from buying a vial and deciding how to use it alone 1, 2.
Legal and regulatory questions patients should verify
Before considering any peptide, patients should verify current FDA approval, compounding, importation, and controlled-substance status using official sources. FDA also warns that compounded drugs are not FDA-approved and do not go through FDA review for safety, effectiveness, or quality before marketing 6, and that unapproved drugs can carry risks because FDA has not evaluated them for safety, effectiveness, or quality 7.
Does Chia sell ARA-290?
Chia does not currently offer ARA-290, cibinetide, PHBSP, or compounded ARA-290. If your goal is nerve pain, inflammation, or a diagnosed medical condition, the right next step is a clinician—not a research-use peptide vial.
How Chia’s clinician-reviewed model works for treatments it does offer
For treatments Chia does offer, care starts online with a short health questionnaire. A licensed US provider reviews eligibility and prescribes only when clinically appropriate; medications are compounded by state-licensed US 503A pharmacies and shipped to the patient’s door.
Longevity-related treatments Chia does offer, without treating them as ARA-290 substitutes
Chia offers several longevity-related treatments, but they are not ARA-290 substitutes. These include Sermorelin, available as injection, nasal spray, and tablets; NAD+, available as injection and nasal spray; and Glutathione, available as injection and nasal spray. Chia also offers protocols such as Foundation Longevity and Glow, when a provider finds them clinically appropriate.
| Chia option | Forms listed in Chia’s catalog | Important note |
|---|---|---|
| ARA-290 / cibinetide / PHBSP | Not offered | Education only; Chia does not currently prescribe or sell it |
| Sermorelin | Injection, nasal spray, tablets | Longevity-related option; not a substitute for ARA-290 |
| NAD+ | Injection, nasal spray | Longevity-related option; not a substitute for ARA-290 |
| Glutathione | Injection, nasal spray | Longevity-related option; not a substitute for ARA-290 |
| Foundation Longevity | Sermorelin Injection + NAD+ Injection + Glutathione Injection | Multi-treatment protocol; eligibility review required |
When to use Chia’s quiz or DoctorMCP for offered treatments
If you want to explore treatments Chia actually offers, you can start with Chia’s online eligibility quiz. If an AI agent is helping you with medication access, Chia is also reachable through DoctorMCP at mcp.chia.health for offered treatments only; ARA-290 is not in Chia’s current catalog.
How should patients evaluate peptide access claims?
Peptide access claims should be checked in a practical, safety-first way. A strong claim about a peptide should answer at least 4 questions: who evaluates you, who makes and dispenses it, what human evidence exists, and what risks are disclosed.
- 1Ask whether a licensed clinician reviews your health history before any medication decision.
- 2Ask whether a compounded medication, if used, is dispensed by a state-licensed 503A compounding pharmacy.
- 3Ask whether the evidence is human randomized evidence, human observational evidence, animal evidence, or cell evidence.
- 4Ask whether the seller separates study findings from marketing claims.
- 5Ask whether side effects, contraindications, storage, sterility, and follow-up are explained.
This same standard applies beyond ARA-290. It is easy for a peptide to sound promising when mechanism studies are described in patient-friendly language. It is harder—and more useful—to ask whether the evidence matches the claim, especially when products are sold through online channels that may not meet safe pharmacy standards 10, 11.
FAQ
Some websites sell ARA-290 peptide, but many position it as a research-use product, not a medication for human use. Chia does not offer ARA-290. If you are considering any peptide, speak with a licensed clinician before using or injecting anything.
Yes. ARA-290 is commonly referred to as cibinetide or PHBSP. These names are used for the same investigational erythropoietin-derived peptide in the medical and commercial literature.
No FDA-approved brand name for ARA-290 was identified in the supplied evidence for this article. It should be treated as investigational, and patients should verify current FDA status using official sources before relying on any access claim.
ARA-290 has been studied in early human trials for painful diabetic neuropathy and sarcoidosis-associated small fiber neuropathy symptoms. Those studies do not prove benefit for general wellness, longevity, or broad pain treatment.
Early studies reported signals in neuropathy-related measures, including symptom scores and corneal nerve fiber density in certain groups. This is not the same as proof that ARA-290 is safe or effective for routine neuropathy treatment.
In one type 2 diabetes neuropathy study, researchers measured outcomes after 28 days of daily study treatment and followed participants through 56 days. That timeline is a research design, not a personal treatment expectation.
No. Chia does not currently offer ARA-290, cibinetide, PHBSP, or compounded ARA-290. Chia’s online care model applies only to treatments listed in its current catalog.
Do not inject or consume a research-use peptide without medical guidance. Save the packaging and product information, and talk with a licensed clinician or poison control if you have used it and feel unwell.
References
- 1.Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine. 2015.
- 2.ClinicalTrials.gov. Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathy Symptoms in Subjects With Type 2 Diabetes Mellitus. NCT02039687. 2014.
- 3.Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular Medicine. 2012.
- 4.Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004.
- 5.Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proceedings of the National Academy of Sciences of the United States of America. 2004.
- 6.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
- 7.U.S. Food and Drug Administration. Know the Risks of Using Drugs Not Approved by FDA. 2024.
- 8.TrueLab Peptides. ARA 290 / Cibinetide (15mg) product information, research-use labeling. 2026.
- 9.BiotechPeptides. ARA-290 (16mg) product information. 2026.
- 10.U.S. Food and Drug Administration. BeSafeRx: How to Buy Medicines Safely From an Online Pharmacy. 2024.
- 11.U.S. Food and Drug Administration. The Possible Dangers of Buying Medicines Over the Internet. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
